SHAWNEE, Kan. — Bayer HealthCare LLC Animal Health has announced that Baytril® 100 (enrofloxacin) Injectable has three new label additions that will increase its versatility and value for swine operators.
Baytril 100 is now the only enrofloxacin FDA-approved for the control of colibacillosis in groups or pens of weaned pigs where colibacillosis associated with E. coli has been diagnosed. It also has been approved for intramuscular (IM) administration for swine and includes a dilution schedule for small pigs.
“Colibacillosis associated with E. coli is a serious threat to the swine industry,” says Andrew Holtcamp, DVM, Senior Veterinary Technical Services at Bayer HealthCare Animal Health. “With these new claims, swine operators using Baytril 100 have a trusted tool that provides versatility beyond swine respiratory disease (SRD) treatment, helping to control this challenging pathogen.”
Baytril 100 is still the only FDA-approved enrofloxacin for treatment and control of six SRD-causing pathogens, including Mycoplasma hyopneumoniae, Bordetella bronchiseptica, Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis and Streptococcus suis.
In addition, Baytril 100 is the only enrofloxacin approved to fight E. coli and for IM administration in swine. Its mode of action kills disease-causing bacteria in both the resting and growth phases, making it an efficient choice for producers.
“The proven 16-year legacy of Baytril 100 combined with these new label additions continues to build on Bayer’s commitment to swine producers, veterinarians and a healthy, nutritious food supply,” says Todd Firkins, Livestock Category Manager at Bayer HealthCare Animal Health.
Source: Baytril